Technology
Health
Pharmaceutical

Athenex

$12.49
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.09 (0.75%) Today
+$0.35 (2.88%) After Hours

Why Robinhood?

You can buy or sell Athenex and other stocks, options, ETFs, and crypto commission-free!

About

Athenex, Inc. Common Stock, also called Athenex, is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer.It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Read More The Oncology Innovation Platform segment involves in discovery and development of cancer supportive therapies. The Global Supply Chain Platform segment consists of manufacturing and marketing of API, medical devices, and clinical products. The Commercial Platform segment engages in manufacturing and selling of commercial pharmaceutical products. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Employees
582
Headquarters
Buffalo, New York
Founded
2003
Market Cap
807.30M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
310.45K
High Today
$12.24
Low Today
$11.91
Open Price
$12.05
Volume
133.22K
52 Week High
$20.90
52 Week Low
$9.83

Collections

Technology
Health
Pharmaceutical
Cancer Prevention
Biopharmaceutical
Medical
Manufacturing
Advertising and Marketing

News

Guru Focus1h

Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $126,000 of Shares

CEO and Chairman of the Board of Athenex Inc (NASDAQ:ATNX) Johnson Yiu Nam Lau bought 10,500 shares of ATNX on 03/20/2019 at an average price of $12 a share.

4
MarketWatchMar 11

Athenex's profit and revenue disappoint

Athenex Inc. ATNX, +1.02% reported a net loss in the fourth quarter as revenue climbed, but less than analysts were expecting, and research and development costs held about steady. Athenex reported a net loss of $27.1 million, compared with a net loss for the comparable quarter a year prior of $28.3 million. The company said it had a net loss of 41 cents a share compared with a net loss of 49 cents a share. Analysts polled by Refinitiv were expecting a net loss of 21 cents a share. The pharmaceutical comp...

50
Yahoo FinanceMar 11

Athenex: 4Q Earnings Snapshot

BUFFALO, N.Y. (AP) _ Athenex Inc. (ATNX) on Monday reported a loss of $27.1 million in its fourth quarter. On a per-share basis, the Buffalo, New York-based company said it had a loss of 41 cents. The biopharmaceutical company posted revenue of $21.3 million in the period. For the year, the company reported that its loss narrowed to $117.4 million, or $1.82 per share. Revenue was reported as $89.1 million. Athenex shares have declined 7 percent since the beginning of the year. The stock has declined 29 ...

1

Earnings

-$0.88
-$0.60
-$0.32
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.20 per share
Actual
-$0.41 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.